Stribild^®: a guide to its use in HIV-1 infection in adults in the EU

The oral fixed-dose elvitegravir/cobicistat/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) single tablet (Stribild^®) is an approved antiretroviral therapy (ART) for the treatment of ART-naive adult patients with HIV-1 infection or those infected with HIV-1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild^®. The low pill burden and convenient administration regimen mean Stribild^® is likely to enhance adherence to treatment. In clinical trials, Stribild^® treatment for up to 144 weeks provided durable suppression of plasma HIV-1 RNA to <50 copies/mL and demonstrated virological efficacy that was noninferior to that of fixed-dose efavirenz/FTC/TDF or a ritonavir-boosted atazanavir plus fixed-dose FTC/TDF regimen.